FDA clears Phase 1 study of Lorus drug
July 19, 2010 by leonardzehr · Leave a Comment
The FDA has approved Lorus Therapeutics’ (TSX:LOR) investigational new drug application for its anti-cancer drug candidate, LOR-253. The company said it now plans to proceed with a first-in-man Phase 1 dose escalation trial with LOR-253 in advanced or metastatic solid tumours at Memorial Sloan-Kettering Cancer Center in New York. The trial will study the safety [...]
Listen to BioTuesdays 
